ARDS Market
                     ARDS Market
Presented by- DelveInsight Business Research

What are the ARDS Market 
Insights?
Furthermore, Pancuronium and Vecuronium are the most commonly used NMBAs for the 
management of ARDS. The use of NMBAs in the ICU, especially in ARDS patients, is not 
marginal. A national US survey performed after 1995, American College of Critical Care 
Medicine/Society of Critical Care Medicine (ACCM/SCCM) guidelines implementation 
showed that Vecuronium (Organon Pharmaceuticals) was routinely used in 18.6% and 
frequently in 30.5% of ICU patients. However, there are inherent risks to the use of 
NMBAs in patients in the ICU. Unrecognized ventilator disconnections can quickly lead to 
hypoxemia and hypercarbia and cause cardiopulmonary collapse. Inadequate sedation 
and analgesia in a paralyzed patient can cause extreme psychologic distress.
In ARDS, the evolution of systemic and pulmonary inflammation in the 1st week of 
mechanical ventilation determines the physiologic progression (resolving vs unresolving) 
and the outcome of the disease. Glucocorticoids as end-effectors of the hypothalamic-
pituitary-adrenal axis are the most important physiologic inhibitors of inflammation, 
affecting hundreds of genes involved in stress-related homeostasis. At the cellular level, 
glucocorticoids exert their effects by activating cytoplasmic heat shock protein-
complexed glucocorticoid receptors, which in turn, interact with activated nuclear factor-
κB to prevent DNA binding and subsequent transcriptional activity.
It is expected that the ARDS Market size of the 
currently available supportive therapies for the treatment 
of ARDS shall experience steady growth throughout the 
study period [2017–2030]. Overall, the increasing 
incidence, awareness of the disease and promising 
emerging pipeline therapies will propel the market size 
forward during the forecast period of 2020–2030.
How Many Regions Are 
Covered?
● The US
● EU5 (Germany, France, Italy, Spain, 
and the United Kingdom)
● Japan
ARDS Market 
Outlook
The ARDS market outlook of the 
report helps to build the detailed 
comprehension of the historic, 
current, and forecasted 
ARDS market trends by analyzing 
the impact of current therapies on 
the market, unmet needs, drivers 
and barriers and demand of better 
technology. 
      Despite decades of research, treatment options for ARDS are 
restricted. Supportive care with mechanical ventilation remains 
the mainstay of management. There are relatively few 
treatments available for ARDS. Other treatment options, which 
the patients with ARDS are subjected to generally include 
supplemental oxygen, prone positioning, use of paralytics, fluid 
management, and a technique called positive end-expiratory 
pressure (PEEP) to help push the fluid out of air sacs. 
These are combined with continuing treatment of the original illness or injury. 
Because people with ARDS are less-abled to fight lung infections, they may develop 
bacterial pneumonia during the illness. Antibiotics are given to fight infection. Also, 
supportive treatment, such as intravenous fluid or food, may be needed.
Original Source:- ARDS Market
[email protected]
[email protected]
+91-9650213330
CREDITS: This presentation template was 
created by Slidesgo, including icons by 
DFola tYiconu,  aHnda invfoeg rAapnhiycs  Q& uimeagsetsi obyn  or 
Freepik
Query?
Please keep this slide for attribution
Than
CREDITS: This presentation template was 
created by Slidesgo, including icons by 
Flaticon, and infographics & images by 
kFresepik !